Oncology CDMOs in United States
17 published
17 published CDMOs match Oncology in United States.
Locations in this set include United States, United Kingdom, China, France, India, and Italy.
Capabilities that show up most often in this set: CMC Analytical Development, Process Development, CMC Regulatory Submission Support, Quality Control Testing, and Technology Transfer.
Matching companies
AldevronAldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.
AltasciencesMid-size early phase CRO/CDMO in Canada and the U.S. offering preclinical safety testing, clinical pharmacology (Phase I–II), bioanalysis, research services, and manufacturing with integrated capabilities.
AxploraGlobal CDMO and API manufacturer specializing in complex small molecule development, ADC manufacturing, HPAPIs, and hazardous chemistry across ten production sites in Europe, India, and the US.- BSP PharmaceuticalsBSP Pharmaceuticals is a CDMO specializing in development and manufacturing of cytotoxic oncology drugs, ADCs, peptides, proteins, and lipid-based formulations from preclinical GLP through commercial supply.
Cellipont BioservicesCellipont Bioservices is a cell therapy CDMO offering end-to-end development, analytical, and cGMP manufacturing services for autologous, allogeneic, CAR-T, and iPSC-derived therapies from preclinical through commercial stages.
Charles River LaboratoriesCharles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.
Cytovance BiologicsU.S.-based CDMO offering end-to-end biomanufacturing services for antibodies, recombinant proteins, vaccines, and other biologics modalities, with dedicated microbial and mammalian facilities and in-house cell line development capabilities.
ElevateBioAdvanced therapies CDMO providing discovery, process development, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA, and gene editing programs from preclinical through commercial scale.
Forge BiologicsDedicated AAV gene therapy CDMO with a 200,000+ sq. ft. cGMP facility featuring 20 suites and bioreactors up to 5,000L, supporting 60+ clients across 35+ indications with high-yield manufacturing and seamless regulatory compliance.
HitGen Inc.HitGen Inc. provides drug discovery services built on DNA-encoded library (DEL), fragment-based (FBDD/SBDD) and computational platforms for pharmaceutical and biotech clients. The company also offers oligonucleotide CDMO services and reports serving more than 600 clients globally.
Oxford BiomedicaGlobal viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.- Roswell Park Comprehensive Cancer CenterRoswell Park Comprehensive Cancer Center in Buffalo, NY is New York State's only National Cancer Institute-designated comprehensive cancer center outside NYC. Its excerpts describe patient cancer care, clinical trials, and research, but do not document GMP manufacturing or contract services for third parties.
Samsung BiologicsLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
Stason Industrial CorporationUS-based CDMO offering contract packaging, analytical testing, and manufacturing services for clinical trial and commercial pharmaceutical production, with specialized high-containment capabilities for potent compounds.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
uBriGeneuBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing.
Markdown mirror: /indications/oncology/us.md